Holen Sie sich die Stockscreener-App
3.85
3.22%
0.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.73
Offen:
$3.74
24-Stunden-Volumen:
2.85M
Relative Volume:
0.56
Marktkapitalisierung:
$1.24B
Einnahmen:
$360.78M
Nettoeinkommen (Verlust:
$-23.91M
KGV:
-49.30
EPS:
-0.0781
Netto-Cashflow:
$13.07M
1W Leistung:
-6.33%
1M Leistung:
-0.77%
6M Leistung:
-31.98%
1J Leistung:
+4.05%
1-Tages-Spanne:
$3.69
$3.85
1-Wochen-Bereich:
$3.63
$4.08
52-Wochen-Spanne:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.85 | 1.24B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD - MarketBeat
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale - Stock Titan
Danbury biopharma company expands workforce, manufacturing amid new product launches - Hartford Business Journal
MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating - MarketBeat
Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD - MarketBeat
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 By Investing.com - Investing.com South Africa
MNKD Maintained by Wells Fargo -- Price Target Lowered to $13.00 - GuruFocus
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says - Yahoo Finance
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 - Investing.com
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth - GuruFocus
MannKind Q2 Earnings Call Highlights - MarketBeat
MNKD SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 By Investing.com - Investing.com Nigeria
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 - Investing.com
Is MannKind Corp (MNKD) Positioned for Growth After Q2 Earnings? - GuruFocus
MannKind Q2 2026 slides: revenue surges 43%, marketed products lead - Investing.com
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MannKind: Q2 Earnings Snapshot - Barchart.com
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary - TradingView
MannKind (NASDAQ: MNKD) posts $199M H1 2026 revenue after scPharma deal - Stock Titan
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
MannKind earnings in focus after FUROSCIX ReadyFlow approval By Investing.com - Investing.com Nigeria
MannKind Corp expected to post breakeven results a shareEarnings Preview - TradingView
Vanguard Capital Management (MNKD) discloses 15.45M-share, 5% MannKind position - Stock Titan
MannKind Reports Positive Topline Results from Phase 1b INFLO-1 Study of Nintedanib Dry Powder Inhalation in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
MannKind Reports Positive Phase 1b INFLO-1 Results, - GlobeNewswire
MannKind (MNKD) to Release Earnings on Wednesday - MarketBeat
MannKind will review second-quarter results in Aug. 5 webcast - Stock Titan
Rubric Capital Management LP Has $8.87 Million Holdings in MannKind Corporation $MNKD - MarketBeat
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - Yahoo Finance
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CT drugmaker raises $50M after FDA approval of new treatment - Hartford Business Journal
H.C. Wainwright reiterates MannKind stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates MannKind stock rating on FDA approval - Investing.com
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):